XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Common Stock and Additional Paid-in Capital [Member]
Parent [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Noncontrolling Interest [Member]
Class A Common Stock (Shares) [Member]
Class B Common Stock (Shares) [Member]
Convertible Preferred Stock
Total CME Group Shareholders' Equity, beginning at Dec. 31, 2018   $ 21,057.9 $ 25,918.5 $ 4,855.3 $ 5.3        
Noncontrolling Interest, beginning balance at Dec. 31, 2018           $ 46.8      
Total Equity at Dec. 31, 2018 $ 25,965.3                
Beginning Balance (in shares) at Dec. 31, 2018             356,824,000 3,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income attributable to CME Group 2,116.5   2,116.5 2,116.5          
Net income (loss) attributable to non-controlling interests           (0.7)      
Net income 2,115.8                
Other comprehensive income/(loss) (1.9)   (1.9)   (1.9)        
Dividends, Cash (1,970.0)   (1,970.0) (1,970.0)          
Impact of accounting standards update adoption 6.9   6.9 6.9          
Changes in non-controlling interest due to measurement period adjustments (15.7)         (15.7)      
Exercise of stock options (in shares)             204,000    
Exercise of stock options 14.2 14.2 14.2            
Vesting of issued restricted Class A common stock, shares             399,000    
Vesting of issued restricted Class A common stock, value (36.8) (36.8) (36.8)            
Shares issued to Board of Directors (in shares)             16,000    
Stock Issued to Board of Directors, Value, Issued for Services 3.2 3.2 3.2            
Shares issued under Employee Stock Purchase Plan (in shares)             26,000    
Shares issued under Employee Stock Purchase Plan 5.2 5.2 5.2            
Stock-based compensation 73.1 73.1 73.1            
Total CME Group Shareholders' Equity, ending at Dec. 31, 2019   21,116.8 26,128.9 5,008.7 3.4        
Noncontrolling Interest, ending balance at Dec. 31, 2019           30.4      
Total Equity at Dec. 31, 2019 26,159.3                
Ending Balance (in shares) at Dec. 31, 2019             357,469,000 3,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income attributable to CME Group 2,105.2   2,105.2 2,105.2          
Net income (loss) attributable to non-controlling interests           1.2      
Net income 2,106.4                
Other comprehensive income/(loss) 131.5   131.5   131.5        
Dividends, Cash (2,117.7)   (2,117.7) (2,117.7)          
Impact of accounting standards update adoption (0.3)   (0.3) (0.3)          
Exercise of stock options (in shares)             123,000    
Exercise of stock options   6.9 6.9            
Vesting of issued restricted Class A common stock, shares             457,000    
Vesting of issued restricted Class A common stock, value (41.4) (41.4) (41.4)            
Shares issued to Board of Directors (in shares)             17,000    
Stock Issued to Board of Directors, Value, Issued for Services 2.9 2.9 2.9            
Shares issued under Employee Stock Purchase Plan (in shares)             44,000    
Shares issued under Employee Stock Purchase Plan 7.9 7.9 7.9            
Stock-based compensation 96.0 96.0 96.0            
Total CME Group Shareholders' Equity, ending at Dec. 31, 2020 26,319.9 21,189.1 26,319.9 4,995.9 134.9        
Noncontrolling Interest, ending balance at Dec. 31, 2020           31.6      
Total Equity at Dec. 31, 2020 26,351.5                
Ending Balance (in shares) at Dec. 31, 2020             358,110,000 3,000 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income attributable to CME Group 2,636.4   2,636.4 2,636.4          
Net income (loss) attributable to non-controlling interests           0.5      
Net income 2,636.9                
Other comprehensive income/(loss) (81.4)   (81.4)   (81.4)        
Dividends, Cash (2,480.4)   (2,480.4) (2,480.4)          
Sale of Stock, Consideration Received on Transaction 965.0 965.0 965.0           $ 1,000.0
Stock Issued During Period, Shares, New Issues                 4,584,000
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests   (20.5)       (32.1)      
Impact of accounting standards update adoption $ (52.6)   (20.5)            
Exercise of stock options (in shares) 101,363           101,000    
Exercise of stock options $ 5.5 5.5 5.5            
Vesting of issued restricted Class A common stock, shares             336,000    
Vesting of issued restricted Class A common stock, value (31.7) (31.7) (31.7)            
Shares issued to Board of Directors (in shares)             14,000    
Stock Issued to Board of Directors, Value, Issued for Services 2.9 2.9 2.9            
Shares issued under Employee Stock Purchase Plan (in shares)             38,000    
Shares issued under Employee Stock Purchase Plan 8.4 8.4 8.4            
Stock-based compensation 75.2 75.2 75.2            
Total CME Group Shareholders' Equity, ending at Dec. 31, 2021 27,399.3 $ 22,193.9 $ 27,399.3 $ 5,151.9 $ 53.5        
Noncontrolling Interest, ending balance at Dec. 31, 2021           $ 0.0      
Total Equity at Dec. 31, 2021 $ 27,399.3                
Ending Balance (in shares) at Dec. 31, 2021             358,599,000 3,000 4,584,000